Vor Bio appoints Sandy Mahatme as CFO and CBO

CAMBRIDGE, Mass. - Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company focused on autoimmune diseases with a market capitalization of $285 million, has appointed Sandy Mahatme as Chief Financial Officer and Chief Business Officer, effective July 9, 2025. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 3.88, though it faces significant cash burn challenges.

Mahatme brings over 30 years of executive leadership experience in the biopharmaceutical industry. He most recently served as President, Chief Operating Officer, and Chief Financial Officer of National Resilience, Inc., a biomanufacturing company he co-founded in 2020, where he raised over $2.5 billion in capital. His appointment comes as Vor Bio’s stock has shown remarkable momentum, with InvestingPro reporting a 169% return over the past year and a 129% gain year-to-date.

Prior to Resilience, Mahatme was Executive Vice President, Chief Financial Officer and Chief Business Officer at Sarepta Therapeutics, leading capital formation efforts exceeding $3.5 billion. He previously held senior positions at Celgene Corporation, Pfizer, Inc., and Ernst & Young, LLP.

"We are thrilled to welcome Sandy to Vor Bio at such a pivotal time in the company’s evolution," said Jean-Paul Kress, Chief Executive Officer and Chairman of the Board, according to the company’s press release.

Vor Bio is currently advancing telitacicept, a dual-target fusion protein, through Phase 3 clinical development for generalized myasthenia gravis outside of China. The treatment has already received approval in China for multiple autoimmune indications.

Mahatme currently serves on the boards of CRISPR Therapeutics and Idorsia Pharmaceuticals. He holds Master of Laws degrees from Cornell Law School and New York University School of Law and is a member of the New York Bar.

As part of his employment agreement, Mahatme received 13,882,750 restricted stock units that will vest over a four-year period, with 25% vesting on July 1, 2026, and the remaining 75% vesting in equal quarterly installments over the following three years. For deeper insights into Vor Bio’s financial health, valuation metrics, and 14 additional ProTips, visit InvestingPro.

In other recent news, Vor Biopharma has made significant strides by entering into an exclusive licensing agreement with RemeGen Co., Ltd. to develop and commercialize telitacicept outside of Greater China. This deal involves an initial payment of $125 million, with $45 million in cash and $80 million in warrants, and includes potential milestone payments exceeding $4 billion. The therapy, which targets autoimmune diseases, is already approved in China for several conditions, including generalized myasthenia gravis and systemic lupus erythematosus. H.C. Wainwright upgraded Vor Biopharma’s stock rating from Neutral to Buy, citing the acquisition of a "de-risked asset" and the strengthening of the company’s portfolio. Meanwhile, Stifel maintained its Hold rating, noting the company’s strategic shift from oncology to autoimmune diseases. Vor Biopharma also secured $175 million in private placement financing, with plans to use the proceeds to advance its clinical pipeline. Additionally, the company announced a leadership change with the appointment of Jean-Paul Kress, M.D., as Chief Executive Officer and Chairman of the Board. Dr. Kress replaces Robert Ang, who will remain as a strategic advisor through October 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.